Skip to main content
PMC home page
Critical Care logoLink to Critical Care
letter
. 2021 Feb 9;25:56. doi: 10.1186/s13054-020-03377-5

Septic shock, noradrenaline requirements and alpha-2 agonists: Fishing in the right pond?

Auguste Dargent 1, Luc Quintin 2,✉, Jean-Pierre Quenot 1
PMCID: PMC7874487  PMID: 33563305

Bellomo et al. [1] confirm the clinical [2–4] data showing a reduction in noradrenaline (NA) requirements in the setting of septic shock following administration of an alpha-2 agonist, dexmedetomidine.

The intensivist is unaware that the retrospective analysis has thoroughly changed the design of the study from “sedation vs. outcome” to “sympathetic de-activation vs. circulation” (i.e., upregulation of alpha-1 receptors vs. NA requirements). Furthermore, the design is not optimal. SPICE III [5] compared early dexmedetomidine (“dex”) versus usual sedation (− 2 < RASS < + 1) [5]. Bellomo achieved RASS ~ − 4, in both groups (results [1]): The dex group received also propofol (95% of the patients), midazolam (43%) and higher doses of opioids (Table S1 [1]). Thus, any effect of dex is drowned as a consequence of adding usual sedation to dex. Nevertheless, in the dex group, (a) the overall NA requirement (“NA equivalent”) is lowered by 25%, nonsignificantly, but of daily clinical relevance for the intensivist; (b) the NA requirement necessary to achieve a target pressure is lowered, as a function of dose (i.e., compatible with a dose-dependent sympathetic de-activation). NA requirements should be readdressed in the dexmedetomidine-only patients versus the usual sedation-only patients, throughout the whole SPICE III [5] database.

Acknowledgements

Not applicable.

Abbreviations

APACHE

Acute Physiology and Chronic Health Evaluation

NA

Noradrenaline

RASS

Richmond agitation-sedation scale

Authors’ contributions

AD, LQ, and JPQ, contributed to the writing. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

LQ received honoraria and unrestricted research grants from Boehringer-Ingelheim, France, UCB Pharma, Belgium, and Abbott International, Il, USA [1986–1996], and holds US patent 8 846 606 B2, September 30, 2014 (method and drug composition for treating septic shock hypotension).

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Cioccari L, Luethi N, Bailey M, Shehabi Y, Howe B, Messmer AS, et al. The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial. Crit Care. 2020;24:441. doi: 10.1186/s13054-020-03115-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pichot C, Mathern P, Khettab F, Ghignone M, Geloen A, Quintin L. Increased pressor response to noradrenaline during septic shock following clonidine? Anaesth Intensive Care. 2010;38:784–785. [PubMed] [Google Scholar]
  • 3.Leroy S, Aladin L, Laplace C, Jalem S, Rosenthal J, Abrial A, et al. Introduction of a centrally anti-hypertensive, clonidine, reduces noradrenaline requirements in septic shock caused by necrotizing enterocolitis. Am J Emerg Med. 2017;35:e3–377. doi: 10.1016/j.ajem.2016.08.027. [DOI] [PubMed] [Google Scholar]
  • 4.Morelli A, Sanfilippo F, Arnemann P, Hessler M, Kampmeier TG, D'Egidio A, et al. The effect of propofol and dexmedetomidine sedation on norepinephrine requirements in septic shock patients: a crossover trial. Crit Care Med. 2018 doi: 10.1097/CCM.0000000000003520. [DOI] [PubMed] [Google Scholar]
  • 5.Shehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, et al. Early sedation with dexmedetomidine in critically Ill patients. N Engl J Med. 2019 doi: 10.1056/NEJMoa1904710. [DOI] [PubMed] [Google Scholar]
  • 6.Lankadeva YR, Ma S, Iguchi N, et al. Dexmedetomidine reduces norepinephrine requirements and preserves renal oxygenation and function in ovine septic acute kidney injury. Kidney Int. 2019;96:1150–1161. doi: 10.1016/j.kint.2019.06.013. [DOI] [PubMed] [Google Scholar]
  • 7.Lankadeva YR, Booth LC, Kosaka J, et al. Clonidine restores pressor responsiveness to phenylephrine and angiotensin II in ovine sepsis. Crit Care Med. 2015;43:e221–e229. doi: 10.1097/CCM.0000000000000963. [DOI] [PubMed] [Google Scholar]
  • 8.Morelli A, Sanfilippo F, Arnemann P, et al. The effect of propofol and dexmedetomidine sedation on norepinephrine requirements in septic shock patients: a cross over trial. Crit Care Med. 2019;47:e89–95. doi: 10.1097/CCM.0000000000003520. [DOI] [PubMed] [Google Scholar]
  • 9.Pichot C, Mathern P, Khettab F, et al. Increased pressor response to noradrenaline during septic shock following clonidine. Anaesth Intensive Care. 2010;38:784–785. [PubMed] [Google Scholar]
Crit Care. 2021 Feb 9;25:56.

Authors’ response

Luca Cioccari 3,4, Rinaldo Bellomo 4,5

We thank Dargent and colleagues for the comments about our study on the hemodynamic changes seen in patients with septic shock treated with dexmedetomidine as primary sedating agent versus usual care [1]. We agree that the retrospective nature of the study creates problems because the original study was a sedation trial with mortality as the outcome, while the retrospective investigation of the hemodynamic effects of dexmedetomidine was a post hoc physiological assessment in patients who were mostly deeply sedated at the time of investigation (median RASS of − 3) and receiving propofol in most cases, fentanyl in the majority and midazolam in close to half of cases. In such a setting, the effect of dexmedetomidine is markedly attenuated by the impact of these drugs. Thus, we agree that it is all the more remarkable that, in the dexmedetomidine group, the overall norepinephrine (noradrenaline) requirements were lower and that the dose required to achieve target mean arterial pressure was also decreased. Finally, we agree that comparing patients on dexmedetomidine only versus patients receiving usual care would be ideal. Unfortunately, we were unable to identify such a cohort of patients. Nonetheless, within the limitations of the design and the population studied, we think that our findings are consistent with a substantial body of experimental data supporting the view that, in the septic, vasodilated state, dexmedetomidine (and central alpha-2 agonists) infusion does not exacerbate hypotension or increase vasopressor requirements but, in fact, appears to do the opposite [6–9].

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    Not applicable.

    Articles from Critical Care are provided here courtesy of BMC

    RESOURCES